These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Endotoxin as a therapeutic target in septic shock. Corriveau CC; Danner RL Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352 [TBL] [Abstract][Full Text] [Related]
4. [Nitric oxide--an important mediator in sepsis?]. Kirkebøen KA; Strand OA Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4061-5. PubMed ID: 10613098 [TBL] [Abstract][Full Text] [Related]
5. Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. Beutler B New Horiz; 1993 Feb; 1(1):3-12. PubMed ID: 7922391 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR; Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555 [TBL] [Abstract][Full Text] [Related]
7. [Is use of nitric oxide (NO) synthase inhibitors justified for therapy of septic shock?]. Jonderko G; Marcisz C; Braclik M Postepy Hig Med Dosw; 2003; 57(1):67-90. PubMed ID: 12765124 [TBL] [Abstract][Full Text] [Related]
9. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J; Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554 [TBL] [Abstract][Full Text] [Related]
10. Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red. Cobb JP Crit Care Med; 1999 May; 27(5):855-6. PubMed ID: 10362394 [No Abstract] [Full Text] [Related]
11. Nitric oxide synthase inhibition in septic shock--a question of the right time, the right drug, and the right model? Bone HG Crit Care Med; 1998 Dec; 26(12):1945-7. PubMed ID: 9875895 [No Abstract] [Full Text] [Related]
12. Pathophysiology of cardiovascular dysfunction in septic shock. Parker MM New Horiz; 1998 May; 6(2):130-8. PubMed ID: 9654320 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse. Rees DD; Monkhouse JE; Cambridge D; Moncada S Br J Pharmacol; 1998 Jun; 124(3):540-6. PubMed ID: 9647479 [TBL] [Abstract][Full Text] [Related]
14. Endotoxin, cytokines, and nitric oxide in shock. Lefer AM Shock; 1994 Jan; 1(1):79-80. PubMed ID: 7538034 [No Abstract] [Full Text] [Related]
16. Interventions for the treatment of septic shock. Figari IS; Palladino MA Ann N Y Acad Sci; 1993 Jun; 685():483-7. PubMed ID: 8363257 [No Abstract] [Full Text] [Related]
17. [Therapeutic perspectives of severe infectious states]. Offenstadt G; Guidet B; Barakett V Rev Prat; 1993 Jan; 43(1):59-64. PubMed ID: 8469900 [TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular dysfunction in septic shock and its treatment]. Dias FS Arq Bras Cardiol; 1993 Jan; 60(1):43-9. PubMed ID: 8240042 [No Abstract] [Full Text] [Related]
19. [Active mediators in the pathogenesis of septic shock and the importance of their neutralization in the treatment of patients]. Bojić I Vojnosanit Pregl; 1996; 53(6):511-8. PubMed ID: 9229971 [No Abstract] [Full Text] [Related]
20. Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Boulos M; Astiz ME; Barua RS; Osman M Crit Care Med; 2003 Feb; 31(2):353-8. PubMed ID: 12576936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]